Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of common stock, which includes the 1,252,500 shares offered pursuant to the underwriters’ full exercise of their option to purchase additional shares. The common stock trades on the Nasdaq Global Select Market under the symbol “ALEC.”

Headquartered in South San Francisco, California, Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.

The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon and associates Dongbiao Shen, Kimberly Wang and Dana Lueck-Mammen. Partner Frank J. Azzopardi and associates Michael V. Policastro and Hilary Smith provided intellectual property and technology advice. The tax team included partner Rachel D. Kleinberg and associate Rebecca A. Rosen. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post